Katarzyna Pogoda, Medical Oncologist at Maria Sklodowska-Curie National Research Institute of Oncology, shared a post on LinkedIn:
“Happy to be part of ESMO Breast Cancer 2026 and to present our study on receptor conversion in residual disease after neoadjuvant therapy in luminal breast cancer.
Among 657 patients, subtype conversion was observed in 40 cases, with treatment adapted in 30 patients. Importantly, conversion to TNBC was associated with worse prognosis. Understanding tumor evolution remains crucial for personalized breast cancer treatment.
Thank you for the fantastic discussions and the opportunity to exchange experiences and perspectives with experts from around the world!”
